Detection of pancreatic cancer using serum protein profiling

Berit Velstra; Bert A. Bonsing; Bart J. Mertens; Yuri E. M. van der Burgt; Anouck Huijbers; Hans Vasen; Wilma E. Mesker; Andre M. Deelder; Rob A. E. M. Tollenaar

doi:10.1111/hpb.12017

Detection of pancreatic cancer using serum protein profiling

Berit Velstra, Bert A. Bonsing, Bart J. Mertens, Yuri E. M. van der Burgt, Anouck Huijbers, Hans Vasen, Wilma E. Mesker, Andre M. Deelder, Rob A. E. M. Tollenaar^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

2 Citations (Scopus)

Abstract

Background: Currently, no suitable biomarkers for the early detection of pancreatic cancer (PC) are available. Proteins present in the serum could reflect a state of the disease. In this study, these profiles as a diagnostic marker for PC were evaluated.

Methods: Serum samples were obtained from PC patients (n = 50 calibration set, n = 39 validation set) and healthy volunteers (n = 110 and n = 75 respectively) according to a uniform standardized collection and processing protocol. For peptide and protein isolation, automated solid-phase extraction (SPE) with Weak Cation Exchange (WCX) magnetic beads (MB) was performed using a 96-channel liquid handling platform. Protein profiles were obtained by mass spectrometry (MS) and evaluated by linear discriminant analysis with double cross-validation.

Results: A discriminating profile for PC has been identified, with a sensitivity of 78% and a specificity of 89% in the calibration set with an area under the curve (AUC) of 90%. These results were validated with a sensitivity of 74% and a specificity of 91% (AUC 90%).

Conclusion: Serum profiles of healthy controls and PC can be discrimated between. Further research is warranted to evaluate specificity and whether this biosignature can be used for early detection in a high risk population.

Original language	English
Pages (from-to)	602-610
Number of pages	9
Journal	HPB
Volume	15
Issue number	8
DOIs	https://doi.org/10.1111/hpb.12017
Publication status	Published - Aug 2013
Externally published	Yes

Keywords

TOF MASS-SPECTROMETRY
ENHANCED LASER-DESORPTION
PROTEOMIC ANALYSIS
GEL-ELECTROPHORESIS
DIAGNOSIS
IDENTIFICATION
ADENOCARCINOMA
BIOMARKERS
PATTERNS
RISK

Access to Document

10.1111/hpb.12017

Cite this

@article{269128a18a25414eac80cd9d1d88b281,

title = "Detection of pancreatic cancer using serum protein profiling",

abstract = "Background: Currently, no suitable biomarkers for the early detection of pancreatic cancer (PC) are available. Proteins present in the serum could reflect a state of the disease. In this study, these profiles as a diagnostic marker for PC were evaluated.Methods: Serum samples were obtained from PC patients (n = 50 calibration set, n = 39 validation set) and healthy volunteers (n = 110 and n = 75 respectively) according to a uniform standardized collection and processing protocol. For peptide and protein isolation, automated solid-phase extraction (SPE) with Weak Cation Exchange (WCX) magnetic beads (MB) was performed using a 96-channel liquid handling platform. Protein profiles were obtained by mass spectrometry (MS) and evaluated by linear discriminant analysis with double cross-validation.Results: A discriminating profile for PC has been identified, with a sensitivity of 78% and a specificity of 89% in the calibration set with an area under the curve (AUC) of 90%. These results were validated with a sensitivity of 74% and a specificity of 91% (AUC 90%).Conclusion: Serum profiles of healthy controls and PC can be discrimated between. Further research is warranted to evaluate specificity and whether this biosignature can be used for early detection in a high risk population.",

keywords = "TOF MASS-SPECTROMETRY, ENHANCED LASER-DESORPTION, PROTEOMIC ANALYSIS, GEL-ELECTROPHORESIS, DIAGNOSIS, IDENTIFICATION, ADENOCARCINOMA, BIOMARKERS, PATTERNS, RISK",

author = "Berit Velstra and Bonsing, {Bert A.} and Mertens, {Bart J.} and {van der Burgt}, {Yuri E. M.} and Anouck Huijbers and Hans Vasen and Mesker, {Wilma E.} and Deelder, {Andre M.} and Tollenaar, {Rob A. E. M.}",

year = "2013",

month = aug,

doi = "10.1111/hpb.12017",

language = "English",

volume = "15",

pages = "602--610",

number = "8",

}

TY - JOUR

T1 - Detection of pancreatic cancer using serum protein profiling

AU - Velstra, Berit

AU - Bonsing, Bert A.

AU - Mertens, Bart J.

AU - van der Burgt, Yuri E. M.

AU - Huijbers, Anouck

AU - Vasen, Hans

AU - Mesker, Wilma E.

AU - Deelder, Andre M.

AU - Tollenaar, Rob A. E. M.

PY - 2013/8

Y1 - 2013/8

N2 - Background: Currently, no suitable biomarkers for the early detection of pancreatic cancer (PC) are available. Proteins present in the serum could reflect a state of the disease. In this study, these profiles as a diagnostic marker for PC were evaluated.Methods: Serum samples were obtained from PC patients (n = 50 calibration set, n = 39 validation set) and healthy volunteers (n = 110 and n = 75 respectively) according to a uniform standardized collection and processing protocol. For peptide and protein isolation, automated solid-phase extraction (SPE) with Weak Cation Exchange (WCX) magnetic beads (MB) was performed using a 96-channel liquid handling platform. Protein profiles were obtained by mass spectrometry (MS) and evaluated by linear discriminant analysis with double cross-validation.Results: A discriminating profile for PC has been identified, with a sensitivity of 78% and a specificity of 89% in the calibration set with an area under the curve (AUC) of 90%. These results were validated with a sensitivity of 74% and a specificity of 91% (AUC 90%).Conclusion: Serum profiles of healthy controls and PC can be discrimated between. Further research is warranted to evaluate specificity and whether this biosignature can be used for early detection in a high risk population.

AB - Background: Currently, no suitable biomarkers for the early detection of pancreatic cancer (PC) are available. Proteins present in the serum could reflect a state of the disease. In this study, these profiles as a diagnostic marker for PC were evaluated.Methods: Serum samples were obtained from PC patients (n = 50 calibration set, n = 39 validation set) and healthy volunteers (n = 110 and n = 75 respectively) according to a uniform standardized collection and processing protocol. For peptide and protein isolation, automated solid-phase extraction (SPE) with Weak Cation Exchange (WCX) magnetic beads (MB) was performed using a 96-channel liquid handling platform. Protein profiles were obtained by mass spectrometry (MS) and evaluated by linear discriminant analysis with double cross-validation.Results: A discriminating profile for PC has been identified, with a sensitivity of 78% and a specificity of 89% in the calibration set with an area under the curve (AUC) of 90%. These results were validated with a sensitivity of 74% and a specificity of 91% (AUC 90%).Conclusion: Serum profiles of healthy controls and PC can be discrimated between. Further research is warranted to evaluate specificity and whether this biosignature can be used for early detection in a high risk population.

KW - TOF MASS-SPECTROMETRY

KW - ENHANCED LASER-DESORPTION

KW - PROTEOMIC ANALYSIS

KW - GEL-ELECTROPHORESIS

KW - DIAGNOSIS

KW - IDENTIFICATION

KW - ADENOCARCINOMA

KW - BIOMARKERS

KW - PATTERNS

KW - RISK

UR - http://www.scopus.com/inward/record.url?scp=84880161321&partnerID=8YFLogxK

U2 - 10.1111/hpb.12017

DO - 10.1111/hpb.12017

M3 - Article

C2 - 23458426

SN - 1365-182X

VL - 15

SP - 602

EP - 610

JO - HPB

JF - HPB

IS - 8

ER -

Detection of pancreatic cancer using serum protein profiling

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this